IntelGenx Technologies (IGXT) Stock Price, News & Analysis

Company Overview

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Key Stats

• Today's Range: $0.17 to $0.17
• 50-Day Range: $0.17 to $0.17
• 52-Week Range: $0.09 to $0.22
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $29.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IntelGenx Technologies Stock Analysis - MarketRank™

IntelGenx Technologies scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for IntelGenx Technologies.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of IntelGenx Technologies is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IntelGenx Technologies is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the outstanding shares of IntelGenx Technologies have been sold short.

Short Interest Ratio / Days to Cover

IntelGenx Technologies has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IntelGenx Technologies does not currently pay a dividend.

Dividend Growth

IntelGenx Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the outstanding shares of IntelGenx Technologies have been sold short.

Short Interest Ratio / Days to Cover

IntelGenx Technologies has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added IntelGenx Technologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IntelGenx Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.05% of the stock of IntelGenx Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

IGXT Stock Analysis - Frequently Asked Questions

How have IGXT shares performed this year?

IntelGenx Technologies' stock was trading at $0.1381 at the start of the year. Since then, IGXT stock has increased by 20.9% and is now trading at $0.1670.
View the best growth stocks for 2024 here.

How were IntelGenx Technologies' earnings last quarter?

IntelGenx Technologies Corp. (OTCMKTS:IGXT) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.01. The business had revenue of $0.51 million for the quarter.

How do I buy shares of IntelGenx Technologies?

Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of IntelGenx Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IntelGenx Technologies investors own include Pfizer (PFE), Tesla (TSLA), Advanced Micro Devices (AMD), Ford Motor (F), Rithm Capital (RITM), Rolls-Royce Holdings plc (RYCEY) and Blink Charging (BLNK).

Company Calendar

• Last Earnings: 11/12/2020
• Today: 11/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IGXT
• CUSIP: 45822R101
• CIK: 1098880
• Web: www.intelgenx.com
• Phone: (514) 331-7440
• Fax: 514-331-0436
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,930,000.00
• Net Margins: -1,049.48%
• Pretax Margin: -1,049.48%
• Return on Equity: N/A
• Return on Assets: -158.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.13
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: $1.04 million
• Price / Sales: 28.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -2.39

Miscellaneous

• Outstanding Shares: 174,660,000
• Free Float: 101,214,000
• Market Cap: $29.17 million
• Optionable: Not Optionable
• Beta: 2.57